Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Paris: AXA (EPA:CS)’s Stock Had Its Neutral Rating Restated at UBS AG in Report Issued Today. Has EUR 22.70 Target

UBS Analyst Rating Change AXA EPA:CS

AXA (EPA:CS) Rating Reconfirmed

They currently have a EUR 22.70 price target on AXA (EPA:CS). UBS AG’s target would suggest a potential downside of -5.53 % from the company’s last Stock close price. This was revealed to clients and investors in a report on Thursday, 22 December.

EPA:CS is currently trading 0.29% higher at EUR 24.07 as of 6:03 PM Frankfurt time. AXA’s stock is 0% in the past 200 days. It has underperformed the S&P500, which has risen 13.64% in the same time.

CS Stock Chart

AXA (EPA:CS) Profile

AXA SA (AXA) is a holding company engaged in the business of financial protection. The Company’s segments include Life & Savings, Property & Casualty, International Insurance, Asset Management, Banking and Holding companies. The Life & Savings segment’s products include a range of investment and savings products, as well as Protection and Health products.

AXA (EPA:CS) traded up 0.29% on 22 December, hitting EUR 24.07. A total of 3.98 million shares of the company’s stock traded hands. This is down from average of 9.16 million shares. AXA has a 52 week low of EUR 16.11 and a 52 week high of EUR 25.5. The company has a market cap of 58.32 billion EUR and a P/E ratio of 9.96.

Get the latest AXA (EPA:CS) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Paris: AXA (EPA:CS)’s Stock Had Its Neutral Rating Restated at UBS AG in Report Issued Today. Has EUR 22.70 Target appeared first on Octafinance.



This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

Paris: AXA (EPA:CS)’s Stock Had Its Neutral Rating Restated at UBS AG in Report Issued Today. Has EUR 22.70 Target

×

Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription

×